CPP-ZFN: A potential DNA-targeting anti-malarial drug
- 8.3k Downloads
Multidrug-resistant Plasmodium is of major concern today. Effective vaccines or successful applications of RNAi-based strategies for the treatment of malaria are currently unavailable. An unexplored area in the field of malaria research is the development of DNA-targeting drugs that can specifically interact with parasitic DNA and introduce deleterious changes, leading to loss of vital genome function and parasite death.
Presentation of the hypothesis
Advances in the development of zinc finger nuclease (ZFN) with engineered DNA recognition domains allow us to design and develop nuclease of high target sequence specificity with a mega recognition site that typically occurs only once in the genome. Moreover, cell-penetrating peptides (CPP) can cross the cell plasma membrane and deliver conjugated protein, nucleic acid, or any other cargo to the cytoplasm, nucleus, or mitochondria. This article proposes that a drug from the combination of the CPP and ZFN systems can effectively enter the intracellular parasite, introduce deleterious changes in its genome, and eliminate the parasite from the infected cells.
Testing the hypothesis
Availability of a DNA-binding motif for more than 45 triplets and its modular nature, with freedom to change number of fingers in a ZFN, makes development of customized ZFN against diverse target DNA sequence of any gene feasible. Since the Plasmodium genome is highly AT rich, there is considerable sequence site diversity even for the structurally and functionally conserved enzymes between Plasmodium and humans. CPP can be used to deliver ZFN to the intracellular nucleus of the parasite. Signal-peptide-based heterologous protein translocation to Plasmodium-infected RBCs (iRBCs) and different Plasmodium organelles have been achieved. With successful fusion of CPP with mitochondrial- and nuclear-targeting peptides, fusion of CPP with 1 more Plasmodium cell membrane translocation peptide seems achievable.
Implications of the hypothesis
Targeting of the Plasmodium genome using ZFN has great potential for the development of anti-malarial drugs. It allows the development of a single drug against all malarial infections, including multidrug-resistant strains. Availability of multiple ZFN target sites in a single gene will provide alternative drug target sites to combat the development of resistance in the future.
KeywordsMalaria Plasmodium Zinc Finger Nuclease Anti Plasmodium Activity Deleterious Change
Malaria is the most devastating human parasitic infection. It threatens half of the world's population, killing more than 1 million people each year [1, 2]. Malaria species vary widely in epidemiology and clinical manifestation [3, 4]. No effective malaria vaccine is currently available, and drug resistance has been implicated in the spread and re-emergence of the disease [5, 6, 7]. Artemisinin drugs, an essential component of treatment for multidrug-resistant falciparum malaria, have recently shown signs of decreased efficacy in combination drug therapy [8, 9, 10, 11, 12].
With the availability of complete genome sequences of Plasmodium, humans and Anopheles-hosts of the parasite, development of novel effective anti malarial drugs was envisioned . However, in spite of eclipse of more than one decade no significant advances have been made in the area of genomics based anti-malarial drug development. Plasmodium genome is highly AT rich as compared to human genome and this opens up opportunities for development of DNA-targeting drugs that can specifically interact with parasite DNA and introduce deleterious changes leading to loss of vital genome function and parasite death. Some DNA targeting drugs such as Aminoquinolines, azaterphenyl diamidines, adozelesin and bizelesin shows anti plasmodium activity, however the problem of cytotoxicity and potential threat of mutagenesis in human DNA is major limiting factor [14, 15, 16].
Presentation of the hypothesis
Advances in the development of zinc finger nuclease (ZFN) with engineered DNA recognition domains allow us to design and develop nuclease of high target sequence specificity [17, 18, 19]. In vivo application of ZFN with a single mega recognition sequence leads to target gene modification in Drosophila, zebra fish, mice, Arabidopsis, rice, tobacco, and other genomes [20, 21, 22, 23, 24, 25], with a gene targeting frequency upto 80% of ZFN-transfected cells . Cell-penetrating peptides (CPP) provide a novel mechanism for intracellular macromolecular delivery [27, 28], CPP are known to cross the cell plasma membrane in a nonspecific manner and deliver conjugated protein, nucleic acid, or any other cargo to the cytoplasm, nucleus, or mitochondria, depending on the additional signal sequences present [27, 29, 30, 31, 32, 33].
ZFN will specifically target the Plasmodium genome.
ZFN can cross the plasma membrane barrier of the host and Plasmodium cell.
DNA double-strand break will kill Plasmodium.
Testing of the hypothesis
Designing specific ZFN
ZFN can be designed specifically against any gene in any genome [21, 22, 36, 37, 38]. C2H2-type zinc finger proteins consist of an array of protein fingers stabilized by zinc ion, with each finger recognizing a specific triplet of DNA sequence . Protein fingers specific for more than 45 triplets are known and have a modular nature, with freedom to change number of fingers, which makes the development of customized ZFP against diverse target DNA sequence feasible (Additional file 1). A combination of 6 fingers recognizes a DNA sequence of 18 nucleotides that have a probability of occurring after 418 nucleotides, much more than the human genome size (3000 MB). Hence, a ZFN designed against the Plasmodium genome have negligible probability of randomly occurring in the human genome. ZFN designing and validation tools, and CompoZr® custom ZFN designing, assembling, and validation service, reduce the time required for the development of ZFN against new targets [39, 40, 41, 42].
Selection of ZFN target sites
Availability of complete genome sequences have helped identify different anti-malarial drug targets, such as histone deacetylase, aspartic proteases or plasmepsins, aminopeptidases, and the purine salvage enzyme hypoxanthine-xanthine-guanine phosphoribosyltransferase, within the parasite [43, 44, 45, 46]. However, limited knowledge on the structure of most of these genes, and on the conservation of basic eukaryotic cellular machinery in Plasmodium and humans, hampers the conventional enzyme-targeting drug design procedures . The Plasmodium genome is highly AT rich, in contrast to the human genome that is GC-rich; this provides considerable sequence (ZFN target) site diversity even for the structurally and functionally conserved enzymes between Plasmodium and humans. ZFN technology can utilize this sequence diversity and overcome the limitations of traditional drug-design approaches, which are confined to parasite-specific metabolic pathways. Moreover, ZFN can be designed against the target site conserved across different Plasmodium species (Additional file 2).
Delivery of ZFN to the target site
Discovery of cell-penetrating peptides provides a novel way of delivering therapeutic molecules to the target cell or organelles [27, 28, 29, 31, 48, 49, 50, 51]. A major challenge in ZFN delivery is developing a peptide that can transfer conjugated ZFN through cell membranes of Plasmodium-infected RBC (iRBC), the parasite, parasitophorous vacuole, and its organelles (apicoplast, mitochondria, or nucleus).
Delivery to RBCs
CPP are generally considered to deliver cargo to cells in a nonspecific manner . iRBCs have different surface proteins and charge that can be utilized for making strategies for specific ZFN delivery. As a matter of evidence, P1 peptides specifically target iRBCs , and DPT-sh1/sh2 CPP specifically recognize and deliver conjugated heterologous proteins to iRBCs .
Translocation from host cell cytoplasm to Plasmodium
Following CPP-mediated ZFN delivery to RBCs, the next challenge is to cross the parasite cell membrane and interact with its DNA. CPP-mediated protein delivery to different intracellular organelles such as the nucleus and mitochondria have been reported [54, 55]. Intracellular Plasmodium imports a number of proteins, such as heme, δ- aminolaevulinate (ALA), and peroxiredoxin 2, from the host cytoplasm [56, 57, 58], which could be a valuable source of signal sequences for translocation of ZFN from the host cytoplasm to the parasite.
Targeting to Plasmodium organelles
Once ZFN enters the Plasmodium, it has to be directed towards any of its organelles-apicoplast, mitochondria, or nucleus-which have their own genome. Use of the yeast GAL4 nuclear localization signal leads to translocation of green florescent protein (GFP) to Plasmodium nucleus and shows conservation of nuclear localization signal in Plasmodium and other eukaryotes . GFP was fused with the N-terminal sequence of heat shock protein (PfHsp); PfHsp-GFP was targeted to Plasmodium mitochondria ; and apicoplast targeting was achieved by using the signal sequence of acyl carrier protein [61, 62, 63].
Availability of iRBCs penetrating peptide ; Plasmodium import proteins [56, 57, 58]; and Plasmodium apicoplast, mitochondria, and nucleus targeting signal sequences [59, 60, 61, 62, 63] provides building blocks for the development of a Plasmodium-targeting, multiple-membrane-traversing peptide. Following the successful fusion of CPP with mitochondrial- and nuclear-targeting peptides [54, 64, 65], fusion of CPP with 1 more Plasmodium cell membrane translocation peptide appears to be achievable.
Hydrolysis of double-stranded DNA
A ZFN-induced double-strand break (DSB) triggers either of the 2 DNA repair processes: error-prone non-homologous end joining (NHEJ) and error-proof homology-dependent repair (HDR). Genetic and biochemical evidence support the hypothesis that NHEJ and HR are 2 independent and competing mechanisms for DSB repair in diploid organisms[66, 67]. Being in the haploid stage in humans, HDR must be absent in Plasmodium and the error-prone repair mechanism of NHEJ often results in localized mutations due to deletion and/or insertion of short sequences at the DSB site, thereby resulting in disruption of functional gene expression in Plasmodium. Moreover, AT-specific DNA alkylating drugs have previously shown anti P. falciparum activity and recent advances in ZFN directed multiple DSB resulting in chromosomal deletions further strengthens the prospects of DNA targeting anti malaria drug [68, 69, 70].
Experimental validation of ZFN therapeutic efficacy
An in silico designed and in vitro validated ZFN is to be evaluated for bioavailability, potency, in vivo localization and their specificity for parasite over human DNA. A microfluorimetric method using PicoGreen® can be used for assessing susceptibility of parasites to CPP-ZFN compounds [71, 72]. Since all ZFN consist of nuclease domain of FokI restriction enzyme so FokI antisera can be used for immuno-localization and quantification of ZFN . Alternatively ZFN are designed to have an additional small protein tag, such as Flag or His tag and subsequently detected by fusion tag specific antibodies . The quantification of DSB repair loci induced by ZFN provide genotoxicity assay, to test any off target effect of parasite specific ZFN over human genome [75, 76].
Implications of the hypothesis
The major advantage of ZFN technology is that it enormously increases the number of drug targets because it can utilize the vast sequence diversity among structurally and functionally conserved enzymes of human and Plasmodium proteins. Prolonged use of any drug forces the evolution of drug-resistant parasite strains, and ZFN would not be an exception. Another advantage of ZFN technology is that it allows convenient development of new ZFN against other target sites (18 bp) in the same gene. The resulting new drug will be effective even against resistant strains, providing ample alternatives for drug resistance management.
Unlike common drugs that directly inhibit the target protein, ZFN technology is focused on inhibiting the synthesis of a functional target protein; thus, its effect will be slower than inhibitor drugs. This constraint may not be a concern as ZFN utilizes the difference between human and Plasmodium gene sequences, so every vital gene becomes a potential drug target. Selection of genomic locus coding for short half-life will greatly enhance the response time of ZFN-based drugs.
Availability of newer drug targets to virtually all Plasmodium genes provides the opportunity to find conserved sites in vital genes and develop a single drug against all malarial infections, including multidrug-resistant strains, for worldwide use. CPP-mediated protein delivery is an established method that can be used for delivery of the newly designed ZFN. CPP-ZFN promises to be a safe and sustainable drug for malaria intervention.
Conflict of interests
The authors declare that they have no competing interests.
The authors are thankful to Drs. Jane Carlton and Steven Sullivan, New York University Langone Medical Center, New York, for their critical reading of the manuscript and for providing valuable suggestions that increased scientific content and presentation of the manuscript.
- 3.Prugnolle F, Durand P, Neel C, Ollomo B, Ayala FJ, Arnathau C, Etienne L, Mpoudi-Ngole E, Nkoghe D, Leroy E, Delaporte E, Peeters M, Renaud F: African great apes are natural hosts of multiple related malaria species, including Plasmodium falciparum. Proc Natl Acad Sci USA. 2010, 107: 1458-1463. 10.1073/pnas.0914440107.PubMedCentralCrossRefPubMedGoogle Scholar
- 4.Jeffares DC, Pain A, Berry A, Cox AV, Stalker J, Ingle CE, Thomas A, Quail MA, Siebenthall K, Uhlemann AC, Kyes S, Krishna S, Newbold C, Dermitzakis ET, Berriman M: Genome variation and evolution of the malaria parasite Plasmodium falciparum. Nat Genet. 2007, 39: 120-125. 10.1038/ng1931.PubMedCentralCrossRefPubMedGoogle Scholar
- 8.Denis MB, Tsuyuoka R, Lim P, Lindegardh N, Yi P, Top SN, Socheat D, Fandeur T, Annerberg A, Christophel EM, Ringwald P: Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Health. 2006, 11: 1800-1807. 10.1111/j.1365-3156.2006.01739.x.CrossRefPubMedGoogle Scholar
- 10.Denis MB, Tsuyuoka R, Poravuth Y, Narann TS, Seila S, Lim C, Incardona S, Lim P, Sem R, Socheat D, Christophel EM, Ringwald P: Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health. 2006, 11: 1360-1366. 10.1111/j.1365-3156.2006.01690.x.CrossRefPubMedGoogle Scholar
- 13.Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan MS, Nene V, Shallom SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin DM, Fairlamb AH, Fraunholz MJ, Roos DS, Ralph SA, McFadden GI, Cummings LM, Subramanian GM, Mungall C, Venter JC, Carucci DJ, Hoffman SL, Newbold C, Davis RW, Fraser CM, Barrell B: Genome sequence of the human malaria parasite Plasmodium falciparum. Nature. 2002, 419: 498-511. 10.1038/nature01097.CrossRefPubMedGoogle Scholar
- 14.Wenzel NI, Chavain N, Wang Y, Friebolin W, Maes L, Pradines B, Lanzer M, Yardley V, Brun R, Herold-Mende C, Biot C, ToÌth K, Davioud-Charvet E: Antimalarial versus Cytotoxic properties of dual drugs derived from 4-aminoquinolines and mannich bases: interaction with DNA. J Med Chem. 2010, 53: 3214-3226. 10.1021/jm9018383.CrossRefPubMedGoogle Scholar
- 24.Remy S, Tesson L, Menoret S, Usal C, Scharenberg AM, Anegon I, Santiago Y, Chan E, Liu PQ, Orlando S, Zhang L, Urnov FD, Holmes MC, Guschin D, Waite A, Miller JC, Rebar EJ, Gregory PD, Klug A, Collingwood TN, Wu J, Kandavelou K, Chandrasegaran S, Mani M, Kandavelou K, Dy FJ, Durai S, Chandrasegaran S: Zinc-finger nucleases: a powerful tool for genetic engineering of animals. Transgenic Res. 2009, 26: 26-Google Scholar
- 25.Shukla VK, Doyon Y, Miller JC, DeKelver RC, Moehle EA, Worden SE, Mitchell JC, Arnold NL, Gopalan S, Meng X, Choi VM, Rock JM, Wu YY, Katibah GE, Zhifang G, McCaskill D, Simpson MA, Blakeslee B, Greenwalt SA, Butler HJ, Hinkley SJ, Zhang L, Rebar EJ, Gregory PD, Urnov FD: Precise genome modification in the crop species Zea mays using zinc-finger nucleases. Nature. 2009, 459: 437-441. 10.1038/nature07992.CrossRefPubMedGoogle Scholar
- 26.Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, Wang N, Lee G, Bartsevich VV, Lee YL, Guschin DY, Rupniewski I, Waite AJ, Carpenito C, Carroll RG, Orange JS, Urnov FD, Rebar EJ, Ando D, Gregory PD, Riley JL, Holmes MC, June CH: Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol. 2008, 26: 808-816. 10.1038/nbt1410.PubMedCentralCrossRefPubMedGoogle Scholar
- 27.Sawant R, Torchilin V, Raagel H, Saalik P, Pooga M, Munst B, Patsch C, Edenhofer F, Gitton Y, Tibaldi L, Dupont E, Levi G, Joliot A, Edenhofer F, Meade BR, Dowdy SF, Gump JM, Dowdy SF, Meade BR, Dowdy SF, Dong X, Wang JN, Huang YZ, Guo LY, Kong X, Murriel CL, Dowdy SF: Intracellular transduction using cell-penetrating peptides. Mol Biosyst. 2009, 6: 628-640. 10.1039/b916297f.CrossRefPubMedGoogle Scholar
- 29.Ward B, Seal BL, Brophy CM, Panitch A, Sawant R, Torchilin V, Raagel H, Saalik P, Pooga M, Munst B, Patsch C, Edenhofer F, Gitton Y, Tibaldi L, Dupont E, Levi G, Joliot A, Edenhofer F, Meade BR, Dowdy SF, Gump JM, Dowdy SF, Meade BR, Dowdy SF, Dong X, Wang JN, Huang YZ, Guo LY, Kong X, Murriel CL, Dowdy SF: Design of a bioactive cell-penetrating peptide: when a transduction domain does more than transduce. J Pept Sci. 2009, 15: 668-674. 10.1002/psc.1168.PubMedCentralCrossRefPubMedGoogle Scholar
- 30.Gitton Y, Tibaldi L, Dupont E, Levi G, Joliot A, Edenhofer F, Meade BR, Dowdy SF, Gump JM, Dowdy SF, Meade BR, Dowdy SF, Dong X, Wang JN, Huang YZ, Guo LY, Kong X, Murriel CL, Dowdy SF: Efficient CPP-mediated Cre protein delivery to developing and adult CNS tissues. BMC Biotechnol. 2009, 9: 40-10.1186/1472-6750-9-40.PubMedCentralCrossRefPubMedGoogle Scholar
- 32.Meade BR, Dowdy SF, Gump JM, Dowdy SF, Meade BR, Dowdy SF, Dong X, Wang JN, Huang YZ, Guo LY, Kong X, Murriel CL, Dowdy SF: Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Adv Drug Deliv Rev. 2008, 60: 530-536. 10.1016/j.addr.2007.10.004.PubMedCentralCrossRefPubMedGoogle Scholar
- 34.Cradick TJ, Keck K, Bradshaw S, Jamieson AC, McCaffrey AP: Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis b virus DNAs. Mol Ther. 2010, 2010: 16-Google Scholar
- 36.Cai CQ, Doyon Y, Ainley WM, Miller JC, Dekelver RC, Moehle EA, Rock JM, Lee YL, Garrison R, Schulenberg L, Blue R, Worden A, Baker L, Faraji F, Zhang L, Holmes MC, Rebar EJ, Collingwood TN, Rubin-Wilson B, Gregory PD, Urnov FD, Petolino JF: Targeted transgene integration in plant cells using designed zinc finger nucleases. Plant Mol Biol. 2009, 69: 699-709. 10.1007/s11103-008-9449-7.CrossRefPubMedGoogle Scholar
- 40.Fu F, Sander JD, Maeder M, Thibodeau-Beganny S, Joung JK, Dobbs D, Miller L, Voytas DF: Zinc Finger Database (ZiFDB): a repository for information on C2H2 zinc fingers and engineered zinc-finger arrays. Nucleic Acids Res. 2009, D279-283. 10.1093/nar/gkn606. 37 DatabaseGoogle Scholar
- 41.Sander JD, Zaback P, Joung JK, Voytas DF, Dobbs D: Zinc Finger Targeter (ZiFiT): an engineered zinc finger/target site design tool. Nucleic Acids Res. 2007, W599-605. 10.1093/nar/gkm349. 35 Web ServerGoogle Scholar
- 42.Mandell JG, Barbas CF: Zinc Finger Tools: custom DNA-binding domains for transcription factors and nucleases. Nucleic Acids Res. 2006, W516-523. 10.1093/nar/gkl209. 34 Web ServerGoogle Scholar
- 47.Dharia NV, Chatterjee A, Winzeler EA: Genomics and systems biology in malaria drug discovery. Curr Opin Investig Drugs. 11: 131-138.Google Scholar
- 53.Guergnon J, Dessauge F, Dominguez V, Viallet J, Bonnefoy S, Yuste VJ, Mercereau-Puijalon O, Cayla X, Rebollo A, Susin SA, Bost PE, Garcia A: Use of penetrating peptides interacting with PP1/PP2A proteins as a general approach for a drug phosphatase technology. Mol Pharmacol. 2006, 69: 1115-1124. 10.1124/mol.105.019364.CrossRefPubMedGoogle Scholar
- 56.Bonday ZQ, Taketani S, Gupta PD, Padmanaban G, Bonday ZQ, Dhanasekaran S, Rangarajan PN, Padmanaban G: Heme biosynthesis by the malarial parasite. Import of delta-aminolevulinate dehydrase from the host red cell. J Biol Chem. 1997, 272: 21839-21846. 10.1074/jbc.272.35.21839.CrossRefPubMedGoogle Scholar
- 58.Koncarevic S, Rohrbach P, Deponte M, Krohne G, Prieto JH, Yates J, Rahlfs S, Becker K: The malarial parasite Plasmodium falciparum imports the human protein peroxiredoxin 2 for peroxide detoxification. Proc Natl Acad Sci USA. 2009, 106: 13323-13328. 10.1073/pnas.0905387106.PubMedCentralCrossRefPubMedGoogle Scholar
- 59.Wittayacom K, Uthaipibull C, Kumpornsin K, Tinikul R, Kochakarn T, Songprakhon P, Chookajorn T: A nuclear targeting system in Plasmodium falciparum. Malar J. 9: 126-10.1186/1475-2875-9-126.Google Scholar
- 65.Yoshikawa T, Sugita T, Mukai Y, Yamanada N, Nagano K, Nabeshi H, Yoshioka Y, Nakagawa S, Abe Y, Kamada H, Tsunoda S, Tsutsumi Y: Organelle-targeted delivery of biological macromolecules using the protein transduction domain: potential applications for peptide aptamer delivery into the nucleus. J Mol Biol. 2008, 380: 777-782. 10.1016/j.jmb.2008.05.047.CrossRefPubMedGoogle Scholar
- 70.Sollu C, Pars K, Cornu TI, Thibodeau-Beganny S, Maeder ML, Joung JK, Heilbronn R, Cathomen T: Autonomous zinc-finger nuclease pairs for targeted chromosomal deletion. Nucl Acids Res. 2010, gkq720.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.